This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 21.05% and 58.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
by Zacks Equity Research
Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 14.29% and 20.62%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and ASLAN Pharmaceuticals Ltd. (ASLN) have performed compared to their sector so far this year.
Aclaris (ACRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 5.66% and 20.16%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Akoya Biosciences (AKYA) have performed compared to their sector so far this year.
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
by Zacks Equity Research
Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with Aclaris' (ACRS) JAK inhibitor met its primary endpoint, it also displays a greater-than-expected placebo effect.
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
by Zacks Equity Research
Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
by Zacks Equity Research
Aclaris (ACRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
by Zacks Equity Research
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 400% and 6.02%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 6.67% and 8.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?
by Zacks Equity Research
Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 4.55% and 36.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?